Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Taiwan | 13 | 2021 | 2556 | 0.45 | Why? |
| Histiocytic Necrotizing Lymphadenitis | 1 | 2010 | 23 | 0.43 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2017 | 309 | 0.29 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.29 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.28 | Why? |
| Virus Shedding | 2 | 2020 | 5834 | 0.27 | Why? |
| HIV Infections | 9 | 2019 | 11620 | 0.26 | Why? |
| Anti-HIV Agents | 4 | 2019 | 2209 | 0.23 | Why? |
| Hepatitis A | 2 | 2018 | 140 | 0.20 | Why? |
| HIV Seroprevalence | 1 | 2018 | 16 | 0.19 | Why? |
| Circumcision, Male | 1 | 2019 | 57 | 0.19 | Why? |
| Hepatitis A Antibodies | 1 | 2017 | 18 | 0.18 | Why? |
| Anti-Retroviral Agents | 2 | 2019 | 1099 | 0.18 | Why? |
| Hepatitis A virus | 1 | 2017 | 68 | 0.17 | Why? |
| Precancerous Conditions | 1 | 2018 | 108 | 0.16 | Why? |
| Autoimmune Diseases | 1 | 2010 | 1996 | 0.16 | Why? |
| Anus Neoplasms | 1 | 2018 | 123 | 0.16 | Why? |
| Herpes Simplex | 1 | 2019 | 272 | 0.15 | Why? |
| Chloroquine | 2 | 2021 | 3152 | 0.15 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.15 | Why? |
| Immunoassay | 2 | 2021 | 4485 | 0.14 | Why? |
| Anal Canal | 1 | 2018 | 367 | 0.14 | Why? |
| Nucleosides | 1 | 2017 | 221 | 0.14 | Why? |
| Papillomaviridae | 1 | 2018 | 404 | 0.13 | Why? |
| Homosexuality, Male | 2 | 2019 | 1158 | 0.12 | Why? |
| Ribavirin | 1 | 2020 | 1182 | 0.12 | Why? |
| Safety | 1 | 2020 | 1583 | 0.12 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.12 | Why? |
| Biological Specimen Banks | 1 | 2020 | 1142 | 0.12 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 451 | 0.12 | Why? |
| Sexually Transmitted Diseases | 1 | 2019 | 694 | 0.11 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Lymphatic Diseases | 1 | 2010 | 96 | 0.10 | Why? |
| Intestinal Mucosa | 1 | 2018 | 1046 | 0.10 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.10 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.09 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.09 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.08 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Sulfonamides | 1 | 2014 | 1294 | 0.07 | Why? |
| Adult | 16 | 2021 | 244371 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Exanthema | 1 | 2014 | 1097 | 0.07 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.07 | Why? |
| Male | 16 | 2021 | 367725 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.06 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.06 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.06 | Why? |
| CD4 Lymphocyte Count | 2 | 2018 | 1517 | 0.06 | Why? |
| Female | 14 | 2021 | 380317 | 0.06 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.06 | Why? |
| Antibody-Producing Cells | 1 | 2021 | 66 | 0.05 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.05 | Why? |
| Viral Load | 2 | 2018 | 15850 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.05 | Why? |
| Recurrence | 1 | 2010 | 3675 | 0.05 | Why? |
| Humans | 23 | 2021 | 930598 | 0.05 | Why? |
| Seroconversion | 2 | 2020 | 2515 | 0.05 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.05 | Why? |
| Autoantibodies | 1 | 2010 | 2094 | 0.05 | Why? |
| Cross Reactions | 2 | 2020 | 4374 | 0.05 | Why? |
| Sexual and Gender Minorities | 2 | 2018 | 1019 | 0.04 | Why? |
| Epitopes | 2 | 2021 | 4113 | 0.04 | Why? |
| Papanicolaou Test | 1 | 2018 | 65 | 0.04 | Why? |
| Binding Sites | 2 | 2021 | 6201 | 0.04 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.04 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.04 | Why? |
| Hepatitis A Vaccines | 1 | 2017 | 52 | 0.04 | Why? |
| Immunoglobulin Fab Fragments | 1 | 2020 | 556 | 0.04 | Why? |
| Heterosexuality | 1 | 2018 | 148 | 0.04 | Why? |
| Serologic Tests | 2 | 2021 | 4359 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Nucleocapsid | 1 | 2021 | 734 | 0.04 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.04 | Why? |
| Cannula | 1 | 2021 | 750 | 0.04 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Patient Participation | 1 | 2021 | 829 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Fever | 1 | 2010 | 7795 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.03 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.03 | Why? |
| Crystallography, X-Ray | 1 | 2020 | 2689 | 0.03 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Cryoelectron Microscopy | 1 | 2020 | 2372 | 0.03 | Why? |
| Papillomavirus Vaccines | 1 | 2018 | 405 | 0.03 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.03 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.03 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.03 | Why? |
| Follow-Up Studies | 1 | 2010 | 17020 | 0.03 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Darunavir | 1 | 2014 | 477 | 0.03 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2017 | 1394 | 0.02 | Why? |
| Sexual Behavior | 1 | 2019 | 1322 | 0.02 | Why? |
| Protein Conformation | 1 | 2020 | 4386 | 0.02 | Why? |
| Aged | 3 | 2021 | 215776 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.02 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.02 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.02 | Why? |
| Vaccination Coverage | 1 | 2018 | 1249 | 0.02 | Why? |
| Risk Factors | 4 | 2018 | 71621 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Protein Domains | 1 | 2020 | 6563 | 0.02 | Why? |
| Child | 2 | 2021 | 70012 | 0.02 | Why? |
| Prognosis | 1 | 2010 | 32490 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.02 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.02 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
Cheng's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(142)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(192)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_